Zenocutuzumab posts durable activity in advanced NRG1 fusion-positive cholangiocarcinoma
Zenocutuzumab produced meaningful antitumor activity in a small but clinically important cohort of patients with advanced NRG1 fusion-positive cholangiocarcinoma, a disease setting with no approved targeted therapy for this molecular subtype. In the phase II eNRGy trial, the HER2 × HER3 bispecific antibody delivered a response rate that is difficult to ignore in a setting where later-line treatment options are often sparse and biologically unfocused.
The signal matters because NRG1 fusions represent a distinct oncogenic driver rather than a broad histologic label. In cholangiocarcinoma, where tumor behavior can be aggressive and systemic therapy options often lose traction quickly, a matched therapy that interrupts ligand-driven HER3 signaling offers a rational way to suppress growth in patients whose tumors appear addicted to this pathway.
Seven of 19 efficacy-evaluable patients responded.
Response kinetics and disease control in a heavily pretreated cohort
The study enrolled 22 patients with advanced NRG1+ cholangiocarcinoma, with a median age of 57.5 years. Patients had already received a median of 1.0 prior therapy, with a range extending from no prior treatment to six previous lines. Among the 18 patients with subtype data available, all had intrahepatic cholangiocarcinoma, which gives the dataset a specific anatomic profile rather than a mixed biliary tract population.
Three patients did not meet the protocol-defined criteria for inclusion in the efficacy analysis, leaving 19 patients for the primary response assessment. Within that group, 7 patients achieved a response, producing an investigator-assessed overall response rate of 36.8% with a 95% confidence interval of 16.3 to 61.6. For an uncommon fusion-driven cholangiocarcinoma subset, that degree of tumor shrinkage is clinically relevant, particularly when standard cytotoxic regimens have already been exhausted or are unsuitable.
The median duration of response reached 7.4 months, and the median time to response was 1.9 months. Rapid tumor regression after treatment initiation is especially valuable in biliary tract cancer, where hepatic tumor burden, biliary obstruction, and declining performance status can narrow the therapeutic window quickly. A median progression-free survival of 9.2 months further suggests that responses were not merely transient radiographic events but part of a broader period of disease control.
HER3 pathway blockade fits the biology of fusion-driven biliary cancer
NRG1 fusions generate an abnormal ligand that activates HER3-centered signaling and drives downstream proliferative and survival pathways. Zenocutuzumab was built to interrupt that biology by targeting HER2 and HER3 simultaneously, disrupting the receptor pairing needed for signal propagation. In a cancer such as cholangiocarcinoma, where actionable alterations are often underrepresented and the disease can evade broad chemotherapy with relative ease, direct pathway inhibition is one of the few strategies that aligns treatment with tumor dependence.
The observed clinical benefit rate of 57.9% supports that concept. In practical terms, disease control in more than half of treated patients suggests that the drug did more than produce isolated partial responses; it also stabilized disease in a meaningful fraction of the cohort. In rare molecular subsets, control can be as consequential as objective shrinkage, especially when the alternative is continued progression through additional empiric therapy.
Safety profile remained manageable through treatment
Tolerability was favorable across the study population. Most treatment-related adverse events were grade 1 or 2, with diarrhea occurring in 27.3% of patients, fatigue in 18.2%, and nausea in 13.6%. One patient experienced grade 3 anemia. No patient discontinued treatment because of an adverse event.
The safety pattern is important for a population that may already be compromised by liver dysfunction, prior chemotherapy, or declining nutritional status. A therapy with measurable antitumor activity but prohibitive toxicity would have limited practical use in cholangiocarcinoma, where maintaining dose intensity and preserving daily function can be as important as radiographic benefit. The absence of treatment discontinuation for adverse events suggests that zenocutuzumab was deliverable in routine clinical conditions reflected by the trial population.
Diarrhea and fatigue are familiar toxicities in oncology, but in this context they did not appear to unravel treatment continuity. The limited rate of severe toxicity gives the regimen a tolerability profile that compares favorably with many standard systemic options used in advanced biliary tract cancer, particularly after first-line therapy has failed.
A small cohort, but a clear molecular signal
This study remains limited by its size, single-arm design, and the narrow molecular population under investigation. The efficacy analysis involved only 19 patients, and the confidence interval around the response rate is wide, which is expected when a rare fusion-defined subgroup is studied. Even so, the combination of response rate, response durability, and manageable toxicity provides a coherent clinical picture rather than a chance finding.
The all-intrahepatic distribution among patients with available subtype data also shapes interpretation. It may reflect the biology of the disease subset captured in the trial, but it also means the findings should not be generalized without caution to every cholangiocarcinoma subtype or every biliary tract cancer histology. The study supports a focused treatment strategy for a specific genomic subgroup, not a blanket claim for all advanced cholangiocarcinoma.
Why these data matter now
Advanced cholangiocarcinoma has long been treated as a disease of histology first and molecular opportunity second. This trial reverses that order for a small but important group of patients whose tumors harbor NRG1 fusions. A median time to response under two months, a median duration of response of 7.4 months, and a progression-free survival approaching nine months create a clinically credible case for targeted therapy in a setting where options have historically been limited.
The next questions are operational rather than rhetorical: where zenocutuzumab fits relative to other targeted agents, how it performs in larger cohorts, and whether earlier use could deepen benefit before patients become too frail for further therapy. For now, the phase II data show that interrupting the HER2-HER3 axis can produce real and durable tumor control in NRG1 fusion-positive cholangiocarcinoma without forcing patients through excessive treatment-related toxicity.